Abeona Therapeutics Announces the Appointment of Michael Amoroso as Chief Operating OfficerGlobeNewsWire • 10/27/20
Abeona Therapeutics’ Board of Directors Forms Special Committee to Oversee Operations, Develop Strategic Direction and Leadership PlanGlobeNewsWire • 10/06/20
Abeona Therapeutics and Taysha Gene Therapies Enter into Licensing and Inventory Purchase Agreements for ABO-202, a Clinical Stage, Novel, One-time Gene Therapy for CLN1 DiseaseGlobeNewsWire • 08/17/20
Abeona Therapeutics Reports Second Quarter Financial Results and Business UpdatesGlobeNewsWire • 08/10/20
Abeona Therapeutics Announces Two Presentations Related to Its RDEB Clinical Program at the Society for Pediatric Dermatology 45th Annual MeetingGlobeNewsWire • 07/10/20
Abeona Therapeutics Announces Appointment of Michael Amoroso as Chief Commercial OfficerGlobeNewsWire • 07/09/20
Abeona Therapeutics Reinitiates Enrollment in EB-101 Pivotal Phase 3 VIITAL™ Study in RDEB after COVID-19 Related Pause and Announces Progress in Patient Enrollment in MPS III StudiesGlobeNewsWire • 07/08/20
Abeona Therapeutics Announces Upcoming Data Presentations at the Society for Pediatric Dermatology 45th Annual MeetingGlobeNewsWire • 06/18/20
Abeona Therapeutics Further Strengthens Board with Appointment of Two New Independent DirectorsGlobeNewsWire • 06/17/20
Is Abeona Therapeutics (ABEO) Outperforming Other Medical Stocks This Year?Zacks Investment Research • 05/28/20
Abeona Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire • 04/21/20
Abeona Therapeutics Appoints Brian Pereira and Shawn Tomasello to the Board of DirectorsGlobeNewsWire • 04/21/20
Implied Volatility Surging for Abeona Therapeutics (ABEO) Stock OptionsZacks Investment Research • 04/20/20
Abeona Therapeutics (ABEO) Moves to Buy: Rationale Behind the UpgradeZacks Investment Research • 03/23/20